METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New prostate cancer shot tested as alternative to daily pills
Disease control Recruiting nowThis study is testing a new injectable form of a prostate cancer hormone therapy called ASP5541. It aims to see if this injection, given every 12 weeks, works as well or better than the standard daily pill version and if it causes fewer side effects. The trial will enroll about 2…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Korean prostate cancer drug safety under watch in major 6-Year study
Disease control Recruiting nowThis study is monitoring the safety of darolutamide, an already approved prostate cancer medication, in 600 Korean patients. Researchers will track side effects and see how well the drug works over time by reviewing patients' medical records during their regular doctor visits. Th…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New prostate cancer injection enters first human tests in china
Disease control Recruiting nowThis early-stage study aims to check the safety and measure how a new drug called ASP5541 moves through the body in Chinese men with advanced prostate cancer. The drug is given as a hip muscle injection alongside standard hormone therapy and prednisone. The main goals are to unde…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for men with spreading prostate cancer
Disease control Recruiting nowThis study is testing whether adding a new experimental drug, JSB462, to standard hormone therapy works better and is safe for men whose prostate cancer has spread but still responds to hormone treatment. It will involve about 150 men and compare the new combination against curre…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New immune weapon tested against advanced prostate cancer
Disease control Recruiting nowThis early-stage study is testing a new drug, JNJ-78278343, that aims to guide the body's own immune cells to attack prostate cancer. It is being given in combination with other standard treatments like immunotherapy, chemotherapy, or hormone therapy. The main goals are to find a…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Targeted radiation zaps prostate cancer in new trial
Disease control Recruiting nowThis study is testing a new radioactive drug called [²¹²Pb]Pb-ADVC001 for men with prostate cancer that has spread. The first part aims to find the safest and most effective dose. The second part will see how well that dose works to control the cancer in different groups of patie…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Why do men skip their cancer pills? french study investigates
Knowledge-focused Recruiting nowThis study aims to understand how well men with advanced prostate cancer stick to their prescribed medication, apalutamide, in real-world settings. It will follow 270 patients in France for one year, using questionnaires to track their adherence and identify factors that make it …
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Janssen Cilag S.A.S. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC
-
Tracking Real-World results for advanced prostate cancer treatment
Knowledge-focused Recruiting nowThis study aims to understand how doctors use the drug darolutamide in real-world clinics to treat men with metastatic prostate cancer that has spread at diagnosis. Researchers will look back at the medical records of about 1,400 men to see who gets the drug, how they take it, an…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:52 UTC